Lipid-Lowering Therapy in CKD: Should We Use It and in Which Patients

Area of Science:

• Nephrology
• Cardiovascular Medicine
• Pharmacology

Background:

• Chronic kidney disease (CKD) significantly elevates risks for mortality and cardiovascular events, persisting even after dialysis initiation.
• Altered lipoprotein structure and function, including diminished high-density lipoprotein antioxidant capacity, are characteristic of CKD.
• The study investigates the impact of lipid-lowering therapy on mortality and cardiovascular outcomes in CKD patients.

Purpose of the Study:

• To evaluate the effectiveness of lipid-lowering therapy in reducing mortality and cardiovascular events in patients with chronic kidney disease.
• To compare the efficacy of lipid-lowering treatments before and after the initiation of dialysis.
• To identify key predictors of mortality in CKD patients, including inflammation and cholesterol levels.

Main Methods:

• The study explored the effectiveness of lipid-lowering therapy on mortality and cardiovascular outcomes.
• Analysis included patients with chronic kidney disease, both pre-dialysis and on dialysis.
• Specific lipid-lowering agents such as statins and fenofibrate were considered in different patient subgroups.

Main Results:

• Mortality in CKD patients shows an inverse association with cholesterol levels, but inflammation and wasting are stronger predictors.
• Lipid-lowering therapy, including statins, reduces death and cardiovascular risks in pre-dialysis patients.
• These therapies are ineffective in reducing mortality once dialysis is initiated, likely due to dominant inflammatory processes.

Conclusions:

• Lipid-lowering therapy is beneficial for pre-dialysis CKD patients but not for those on dialysis.
• Inflammation, rather than cholesterol levels, is a critical factor driving adverse outcomes in dialysis patients.
• Fenofibrate may reduce cardiovascular events and slow disease progression in type 2 diabetic patients with CKD not yet on dialysis.